Despite the fact that more than a third of U.S. adults are obese, it's been an uphill battle for developers of obesity treatments.» Read More
CNBC's Jim Cramer on Wednesday identified two biotechnology stocks that he thinks could climb.
AstraZeneca took steps to build up its respiratory medicine business by striking a deal to acquire the rights to lung drugs developed by Almirall.
Regeneron Pharmaceuticals said the U.S. Food and Drug Administration has approved the use of Eylea for the treatment of diabetic macular edema.
Amgen posted higher-than-expected profit and said it would cut 12 to 15 percent of its workforce and close two plants.
Pfizer CEO Ian Read also says a potential U.S. tax holiday would be only a temporary solution.
Pfizer reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.
Merck reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition.
Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.
Reckitt Benckiser plans to spin off its heroin-addiction treatment in the next 12 months as sales slide under pressure from rival versions.
GSK's chief executive has opened the possibility of the group being broken up as he pushes through a sweeping overhaul of Britain's biggest drugmaker.
Gilead Sciences delivered quarterly earnings and revenue that topped analysts' expectations on Wednesday.
CNBC's Dominic Chu takes a look at the big movers in biotech on Wednesday.
U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.
Puma Biotechnology's experimental breast cancer drug met its main goal in a late-stage trial, but the options market is sensing something funky.
Washington needs to stop trying to force companies to stay in the US and address the real problem, says Edward J. Reilly of FTI Consulting.
Allergan on Monday said that its second-quarter profit and sales rose, and it announced $475 million in cost cuts.
States may be on the hook for $55 billion to pay for hepatitis C treatments like Sovaldi, a new study says.
Novartis and Google have agreed to develop "smart" contact lenses to help diabetics track blood glucose levels or restore the eye's ability to focus.
The liver disease NASH is becoming more widespread, and the market for treatments may rival those for hepatitis C.
Mylan said it would buy Abbott Labs' generics business outside the United States in an all-stock transaction valued at about $5.3 billion.
Get the best of CNBC in your inbox